June 20, 2025 10:48 AM EDT

UK's NICE says Lilly, Eisai's Alzheimer's drugs aren't worth national coverage

Lei Lei Wu

News Reporter

Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla should not be covered under the UK’s national health insurance because the Alzheimer’s drugs’ benefits don’t outweigh …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

UK's NICE says Lilly, Eisai's Alzheimer's drugs aren't worth national coverage

Lei Lei Wu

News Reporter

Sign up to read this article for free.

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

Inside the FDA’s ‘listening’ tour: Officials agree US lags behind China on drug development

Pharma companies are weighing how a drug’s IP location could impact tariffs

Early-stage investor Syncona readjusts priorities due to bleak biotech market

Roche's venture arm chief to step down in 2026; AstraZeneca obesity leader has retired

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

UK's NICE says Lil­ly, Ei­sai's Alzheimer's drugs aren't worth na­tion­al cov­er­age

Lei Lei Wu

News Reporter

Sign up to read this article for free.

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

In­side the FDA’s ‘lis­ten­ing’ tour: Of­fi­cials agree US lags be­hind Chi­na on drug de­vel­op­ment

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

Ear­ly-stage in­vestor Syn­cona read­justs pri­or­i­ties due to bleak biotech mar­ket

Roche's ven­ture arm chief to step down in 2026; As­traZeneca obe­si­ty leader has re­tired

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

UK's NICE says Lilly, Eisai's Alzheimer's drugs aren't worth national coverage

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

Inside the FDA’s ‘listening’ tour: Officials agree US lags behind China on drug development

Pharma companies are weighing how a drug’s IP location could impact tariffs

Early-stage investor Syncona readjusts priorities due to bleak biotech market

Roche's venture arm chief to step down in 2026; AstraZeneca obesity leader has retired

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?